copy and paste this google map to your website or blog!
Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples: WordPress Example, Blogger Example)
Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer
(Any information to deal,buy, sell, quote for products or service)
CanAg - Fujirebio Fujirebio has over 20 years of experience in the manufacture and supply of manual enzyme immunoassay (EIA) kits for a range of disease states Our manual EIA kits are available for research and In Vitro Diagnostics use We offer EIA kits for multiple biomarkers and disease states
Potential of Anti-MUC1 Antibodies as a Targeted Therapy for . . . In a phase I trial, Cantuzumab was conjugated to an anti-microtubule agent mertansine (DM1) and different doses were used to treat colon and rectum carcinomas or other malignancies with positive CanAg antigen as a single intravenous infusion
CanAg Travel - F. A. R. M. S. Guidelines on baggage are provided for information purposes only and under no circumstances is CanAg Travel liable for baggage Please check with the respective airline if more information is required
Cantuzumab - Wikipedia "HuC242 binds to the extracellular domain of the tumor-associated carbohydrate antigen known as CanAg (a novel glycoform of MUC1) CanAg is strongly expressed in most pancreatic, biliary, and colorectal cancers
What are CanAg inhibitors and how do they work? - Patsnap CanAg inhibitors, short for Cancer Antigen inhibitors, are a class of therapeutic agents designed to specifically target proteins or antigens that are overly expressed on the surface of cancer cells
Company Profile-CanAg Diagnostics (Beijing) Co. , Ltd. Fujirebio Diagnostics have maintained the CanAg brand name for those EIA kits that CanAg customers around the world have come to associate with superior quality and reliability
IKS04, a CanAg-Targeting Antibody–Drug Conjugate with . . . CanAg (CA242) is a carbohydrate antigen highly overexpressed in most gastrointestinal cancers, with minimal expression in normal tissue, making it an attractive target for antibody–drug conjugate (ADC) therapeutics in these cancers
CanAg® Glypican-3 EIA - Fujirebio The CanAg Glypican-3 EIA is a manual enzyme immunometric assay for the quantitative determination of Glypican-3 in human serum The assay is indicated for use as an aid in the diagnosis of hepatocellular carcinoma (HCC)